Significant treatment-specific differences in PFS were observed in patients with...an 18-gene tumor inflammation signature (TIS) (Interaction P-value: 0.001)....High TIS score was associated with significantly longer PFS in the tislelizumab plus chemotherapy group, but not in the chemotherapy alone group....This exploratory analysis of RATIONALE-307 is the first Phase 3 trial indicating a strong association between TIS score and clinical benefit of PD-1 blockade plus chemotherapy vs chemotherapy alone in sq-NSCLC.